Kei Mizuno

Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.

M. Gleave, A. Sboner, A. Wyatt, 2023, Journal of the National Cancer Institute.

Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer

H. Beltran, Sheng-Yu Ku, Yasutaka Yamada, 2023, Science Translational Medicine.

Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation

H. Beltran, G. Franceschini, E. Corey, 2023, Cancer discovery.

Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer

H. Beltran, L. Puca, M. Long, 2024, The Journal of clinical investigation.

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

M. Tolstorukov, H. Beltran, D. Rickman, 2024, Research square.

Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide

Takayuki Goto, S. Akamatsu, Yoshifumi Miyawaki, 2023, Cancer science.